Skip to content
Screener

Insight Molecular Diagnostics Inc. IMDX Q1 2026 earnings

Reported May 13, 2026 · After market close

Revenue$32.0KMiss by $197.2K
EPS-$0.28Miss by $0.02
Revenue estimate$229.2K
EPS estimate-$0.26

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$215.1K
EPS estimate-$0.23

Financials

Q1 2026

Income statement

See full
Revenue$32.0K-98.5%
Gross profit$15.0K-98.9%
Operating income-$4.4M+35.1%
Net income-$4.3M+35.7%
EPS (diluted)-$0.12+53.8%

Balance sheet

See full
Cash & equivalents$28.2M-9.1%
Total debt$2.9M-13.5%
Total equity-$10.7M-205%
Total assets$40.4M-33.0%

Cash flow

See full
Operating cash flow-$7.6M-30.8%
CapEx$613.0K+99.7%
Free cash flow-$8.3M-34.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$105.51M—
Enterprise value$80.2M—
P/S54.1×—

Profitability

See full
Gross margin50.7%-3.6pp
Operating margin-2,500.7%+4,459pp
Net margin-2,454.6%+4,017pp
FCF margin-1,409.7%-6,023pp

Returns & leverage

See full
Current ratio2.5×-1.2×

FAQ

When did Insight Molecular Diagnostics Inc. report Q1 2026 earnings?
Insight Molecular Diagnostics Inc. (IMDX) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Insight Molecular Diagnostics Inc.'s Q1 2026 revenue and EPS?
Insight Molecular Diagnostics Inc. reported revenue of $32.0K and eps of $-0.28 for Q1 2026.
Did Insight Molecular Diagnostics Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $229.2K by $197.2K. EPS missed the consensus estimate of $-0.26 by $0.02.
How did Insight Molecular Diagnostics Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 98.5% from $2.1M a year earlier and eps declined 7.7% from $-0.26.
Where can I find Insight Molecular Diagnostics Inc.'s Q1 2026 SEC filings?
You can read the 8-K/A earnings release (0001493152-26-022708) and the 10-Q periodic report (0001642380-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.